Clinical Significance of Detection of Coagulation Indexes, Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China
Background: To investigate the clinical significance of monitoring the coagulation indexes, immune factors and inflammatory factors in pregnancy-induced hypertension syndrome (PIH).
Methods: 90 pregnant women with PIH admitted in Weihaiwei People's Hospital of Shandong Province, China from 2016 to 2017 were collected, including 45 cases in mild-moderate group and 45 cases in severe group. Another 45 normal pregnant women at the same period were selected as control group. The immune indexes, four index signs of coagulation bloods and serum inflammatory factors in three groups of subjects were determined.
Results: The levels of complement 3 (C3), complement 4 (C4), immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) were successively increased in severe PIH group, mild-moderate PIH group and normal pregnancy group (P<0.05). Compared with those in normal pregnancy group, the levels of PT, APTT and TT were significantly decreased and Fib levels were significantly increased in PIH groups (P<0.05). Compared with those in normal pregnant women, the levels of TNF-α and IL-6 in pregnant women with PIH were significantly increased (P<0.05), and the changes in severe PIH group were more obvious than those in mild-moderate group.
Conclusion: Pregnant women with PIH are in a hypercoagulable state and have a higher risk of thrombus and secondary hyperfibrinolysis. Immune factors and inflammatory factors are also associated with the occurrence and development of the disease. Monitoring the changes in coagulation indexes and levels of immune factors and inflammatory factors provide an important reference value for clinical treatment and prevention of complications.
2. Yamada T, Ishikawa S, Kataoka S et al (2013). Coagulation/fibrinolysis and la-boratory characteristics of pregnant woman with severly depressed an-tithrombin activity. Hypertens Pregnancy, 32(3): 235-244.
3. Wang L, Liu ZQ, Huo YQ, Yao LJ, Wei XG, Wang YF (2013). Change of hs-CRP, Svcam-1, NT-proBNP levels in pa-tients with pregnancy-induced hyperten-sion after therapy with magnesium sulfate and nifudipine. Asian Pac J Trop Med, 6(11): 897-901.
4. Takamagi S, Yamabe H (2013). Relationship between body mass index and course of pregnancy in women. Health, 5(25): 1976-1982.
5. Jie Le (2008). Gynecology and Obstetrics.Version 7. Beijing: People's Medical Publishing House, 93-101. (In Chinese).
6. Ganzevoort W, Rep A, Bonsel GJ, De Vries JI, Wolf H (2012). Dynamics and inci-dence patterns of maternal complications in early-onset hypertension of pregnancy. BJOG, 114(6):741-50.
7. Cramer TJ, Gale AJ (2012). The anticoagu-lant function of coagulation factor V. Thromb Haemost, 107(1):15-21.
8. Kim JS, Kang EJ, Woo OH et al (2013). The relationship between preeclampsia, preg-nancy-induced hypertension and mater-nal risk of breast cancer: A meta-analysis. Acta Oncol, 52(8):1643-8.
9. Persson E, Olsen OH (2011). Allosteric acti-vation of coagulation factor Ⅶa. Front Bi-osci (Landmark Ed), 16: 3156-63.
10. Caballo C, Escolar G, Diazricart M et al (2013). Impact of experimental haemodi-lution on platelet function, thrombin gen-eration and clot firmness: effects of dif-ferent coagulation factor concentrates. Blood Transfus, 11(3): 391-399.
11. Pabinger I, Grafenhofer H, Kaider A et al (2001). Preeclampsia and fetal loss in women with history of renous throm-boemblism. Alte Rioscler Throbvosc Biol, 21(5): 874-9.
12. Girouard J, Giguere YJ, Forest J (2007). Pre-vious hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension, 49(5): 1056-62.
13. Wilczyński JR, Tchórzewski H, Głowacka E et al (2002). Cytokine secretion by decidu-al lymphocytes in transient hypertension of pregnancy and preeclampsia. Mediators lnflamm, 11(2): 105-11.
14. Scholz W, McClurg MR, Cardenas GJ, Smith M, Noonan DJ, Hugli TE, Morgan EL (1990). C5a-mediated release of inter-leukin-6 by human monocytes. Clin Immu-nol Immunopathol, 57(2): 297-307.
15. Petrucco O, Thomson N, Lawrence, Wel-don MW (1974). Immunofluorescent studies in renal biopsies in preeclampsia. Br Med J, 1(5906): 473-6.
16. Yang SL, Kleinman AM, Wei PY (1975). Immunologic aspect of term pregnancy tomemia: A study of immunoglobulins and complement. Am J obstec Gynecol, 122(6): 727-31.
17. Fiers W (1991). Tumor necrosis factor. Characterization at the molecular cellular and vivo level. FEBS Lett, 285(2): 199-212.
18. Kalantar F, Rajaei S, Heidari AB, Mansouri R, Rashidi N, Izad MH, Mirahmadian M (2013). Serum levels of tumor necrosis factor-alpha.interleukin-15 and interleu-kin-10 in patients with pre-eclampsia in comparison with normotensive pregnant woman. Iran J Nurs Midwifery Res, 18(6): 463-6.
19. Mohajertehran F, Tavakkol AJ, Rezaieyazdi Z, Ghomian N (2012). Association of single nucleotide polymorphisms in the human tumor necrosis factor-alpha and interleukin 1-beta genes in patients with pre-eclampsia. Jran J Allergy Asthma Immu-nol, 11(3): 224-9.
20. Parrish MR, Murphy SR, Rutland S et al (2010). The effect of immune factors. tumor necrosis factor-alpha, and agonis-tic autoantibodies to the angiotensin Ⅱ type Ⅰ receptor on soluble fms-like trro-sine-1 and soluble endolin production in response to hypertension during preg-nancy. Am J Hypertens, 23(8):911-6.
21. Ram K, Santoro N (2005). Does Pregnancy-induced Hypertension increase the risk of developing metabolic syndrome. Nat Clin Pmct Ednocironl Metab, l (2):76-7.
|Issue||Vol 48 No 4 (2019)|
|Coagulation index Immune factor Pregnancy-induced hypertension syndrome|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|